SCHEMBL1403657

SCHEMBL1403657

COC(=O)c1ccc(NCc2ccco2)cc1C(=O)OC

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.59
ALDH1A1 P00352 4/20 0.59
GAA P10253 2/20 0.59
MAPT P10636 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
MAPK1 P28482 3/20 0.52
APP P05067 1/20 0.52
EGFR P00533 4/20 0.49
NOX4 Q9NPH5 1/20 0.49
AQP1 P29972 1/20 0.47
HSD17B10 Q99714 3/20 0.47
SHMT2 P34897 1/20 0.46
TSHR P16473 3/20 0.46
LMNA P02545 1/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1403660 0.83 KDM4E (0.58) KDM4EALDH1A1GAAMAPTTDP1
SCHEMBL1403631 0.82 ALDH1A1 (0.63) KDM4EALDH1A1GAAMAPTTDP1
SCHEMBL1403639 0.77 CA1 (0.66) KDM4EALDH1A1GAAEGFRNOX4
SCHEMBL1403511 0.77 KDM4E (0.53) KDM4EALDH1A1MAPTEGFRNOX4
SCHEMBL28603982 0.77 KDM4E (0.62) KDM4EALDH1A1GAAMAPTTDP1
SCHEMBL17308821 0.76 KDM4E (0.57) KDM4EALDH1A1GAAMAPTTDP1
SCHEMBL17774918 0.76 ALDH1A1 (0.55) KDM4EALDH1A1GAAMAPTTDP1
SCHEMBL3800591 0.75 KDM4E (0.60) KDM4EALDH1A1MAPTTDP1MAPK1
SCHEMBL10224352 0.74 APP (0.70) KDM4EALDH1A1GAAMAPTTDP1
SCHEMBL12522426 0.74 APP (0.58) KDM4EALDH1A1GAAMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3327013-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2019-04-24 EP disclosed
EP-3327013-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS Celgene Corporation (US) 2018-05-30 EP disclosed
EP-3061758-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2018-01-31 EP disclosed
US-9801868-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2017-10-31 US disclosed
US-20160346264-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2016-12-01 US disclosed
US-9447070-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2016-09-20 US disclosed
EP-3061758-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS Celgene Corporation (US) 2016-08-31 EP disclosed
EP-2749559-B1 5-substituted isoindoline compounds CELGENE CORP (US) 2016-04-27 EP disclosed
EP-2291365-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2015-03-11 EP disclosed
US-20150005303-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2015-01-01 US disclosed
US-8877780-B2 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2014-11-04 US disclosed
EP-2749559-A1 5-substituted isoindoline compounds CELGENE CORPORATION (US) 2014-07-02 EP disclosed
EP-2057143-B1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORP (US) 2013-07-24 EP disclosed
EP-2291365-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2011-03-09 EP disclosed
WO-2009145899-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2009-12-03 WO disclosed
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION 2009-06-04 US disclosed
EP-2057143-A2 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2009-05-13 EP disclosed
WO-2008027542-A2 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CELGENE CORPORATION (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160346264-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 KDM4E 2637/4885ALDH1A1 403/4885GAA 1763/4885
US-20150005303-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 KDM4E 2637/4885ALDH1A1 403/4885GAA 1763/4885
US-20090142297-A1 5-SUBSTITUTED ISOINDOLINE COMPOUNDS CYP3A5, CYP3A7, CYP3A4 KDM4E 2637/4885ALDH1A1 403/4885GAA 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.